Ambroxol, a cough medication, may help stabilize the neuropsychiatric symptoms of Parkinson's disease dementia, a new study ...

An active ingredient in cough medicines since 1979 has shown promise as a treatment for neuropsychiatric symptoms in ...

Ambroxol is commonly used as an expectorant in cough syrup, helping thin out mucus so people with respiratory illnesses can ...

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

A safe and affordable treatment to slow the advancement of Parkinson's dementia has emerged – in the form of a commonly ...

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people ...

Ambroxol – a common cough medicine in Europe – may prevent the progression of dementia in patients with Parkinson's disease, a new trial suggests.

A 12-month study found that Ambroxol helped stabilised psychiatric symptoms and protected against brain damage in genetically ...

A common cough syrup, Ambroxol, has shown potential in slowing the progression of Parkinson's dementia in a recent clinical trial.

A 12-month clinical trial investigated whether a cough medicine used in Europe called Ambroxol can slow dementia in people with Parkinson’s.

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson's disease, GCase levels are often low.

Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...